Relief therapeutics and acer therapeutics announce that the european commission has granted orphan drug designation for acer-001 in maple syrup urine disease

Orphan designation provides potential for up to 10-year market exclusivity in the eu upon regulatory approval orphan designation provides potential for up to 10-year market exclusivity in the eu upon regulatory approval
ACER Ratings Summary
ACER Quant Ranking